Ken Greathouse

Ken Greathouse is a serial entrepreneur focused on the specialty pharmaceutical market. He has co-founded 5 specialty pharmaceutical, development-stage, companies over the past 20 years and 1 commercial-stage rare disease company, Manchester Pharmaceuticals, which was sold in 2015 to Retrophin, Inc. Ken is currently President of Argent Development Group, LLC, which he co-founded in 2004, and CEO of Melbourne Laboratories and Newcastle Bioscience. Ken was formerly Senior Vice President of Commercial Operations for Questcor Pharmaceuticals, a subsidiary of Mallinckrodt. Prior to his tenure at Questcor, Mr. Greathouse served as General Manager of Athena Neurosciences, a division of Elan Pharmaceuticals, PLC. Before joining Athena, Mr. Greathouse held a number of commercial positions with Lederle Laboratories over an 18-year span that included Sales, Marketing and Business Development. Ken is married to Sue Greathouse and has 3 sons and 2 grandchildren. Ken holds a Bachelor’s degree in Business from the University of California at Berkeley and is an alumnus of the Harvard Business School.